In the Restasis case, Faruqi & Faruqi represents a proposed class of direct purchasers of Restasis. The direct purchasers alleged that the drug’s manufacturer, Allergan, Inc., delayed entry of a generic version of Restasis by procuring patents by fraud, listing those fraudulently acquired patents in the Orange Book, filing serial sham petitions with the FDA, and transferring ownership of the fraudulently acquired patents to the Saint Regis Mohawk Tribe and asserting the Tribe’s sovereign immunity. A settlement of $51 million was reached with Allergan in February 2020 and was finally approved by the court on October 7, 2020.
Send Information
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.
Details
Filed on 12/11/2017
Office
1617 JFK Boulevard, Suite 1550
19103 Philadelphia, Pennsylvania
Phone (215) 277-5770
Fax (215) 277-5771
Counsel
Joseph T. Lukens jlukens@faruqilaw.com Phone (215) 277-5770 Fax (215) 277-5771
Peter Kohn pkohn@faruqilaw.com Phone (215) 277-5770 Fax (215) 277-5771